treating a subject having ~~non-small cell lung~~ pancreatic cancer, wherein the treating comprises the oral administration of the medicament and the administration of at least one additional therapeutic agent comprising a platinum agent.

[0019] Certain embodiments herein provide methods of using the formulations provided herein to treat, prevent, or manage diseases or disorders including, *e.g.*, cancer, disorders related to abnormal cell proliferation, solid tumors, hematologic disorders, or immune disorders. In certain embodiments, the formulations of cytidine analogs are orally

Claims

1. Use of 5-azacytidine, or a pharmaceutically acceptable hydrate thereof, and at least one pharmaceutically acceptable excipient in the manufacture of a medicament for treating a subject having ~~non-small cell lung~~ pancreatic cancer, wherein the treating comprises the oral administration of the medicament and the administration of at least one additional therapeutic agent comprising a platinum agent.

2. The use of claim 1, wherein the ~~non-small cell lung~~ pancreatic cancer is a relapsed or refractory ~~non-small cell lung~~ pancreatic cancer.

3. The use of claim 1, wherein the additional therapeutic agent is carboplatin.

4. The use of any one of claims 1 to 3, wherein treating the subject comprises the sequential steps of:

(i) administering 5-azacytidine to the subject for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days; and

(ii) administering the additional therapeutic agent to the subject for one or more days.